Physician profile
Weiwei Cao
NPI 1992987283
$4,093.36
in general payments reported to CMS, 2019-2025
11 companies · $70.24 in 2025
The $70.24 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.64 · 2020: $1,758 · 2022: $1,727 · 2023: $424 · 2024: $77.86 · 2025: $70.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $572.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Uk Limited | $3,335.00 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $239.67 | 2022-2023 | Ocaliva |
| E.R. Squibb & Sons, L.L.C. | $133.22 | 2023 | Zeposia |
| Pfizer INC. | $132.79 | 2019-2025 | |
| Abbvie INC. | $97.75 | 2023-2024 | Rinvoq, Linzess, Viberzi |
| Celgene Corporation | $54.64 | 2023-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $28.45 | 2023 | Recarbrio, Dificid, Zerbaxa |
| Janssen Biotech, INC. | $27.79 | 2020-2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $20.06 | 2019 | |
| Phathom Pharmaceuticals, INC. | $18.82 | 2024 | Voquezna |
| Romark Laboratories, Lc | $5.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weiwei Cao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.